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osting by EAbstract Despite the fact that CABG is the standard of care for patients with multivessel coronary
arteries and/or left main stem stenosis, PCI has become a rival to CABG in patients with multivessel
coronary artery disease or left main disease. However, the need for repeat revascularization, in-stent
stenosis and thrombosis remain the achilis heal of PCI. SYNTAX trial randomized patients with
left main disease and/or three-vessel disease to PCI with TAXus stent or CABG with the concept
that PCI is not inferior to CABG. At 1 and 2 years follow up, MACCE was signiﬁcantly increased
in PCI patients mainly attributed to increased rate of repeat revascularization; however, stroke was
signiﬁcantly more with CABG. The composite safety endpoint of death/stroke/MI was comparable
between the 2 groups. Therefore the criterion for non-inferiority was not met. What we learn from
SYNTAX is that multi disciplinary team approach should be the standard of care when recom-
mending treatment in more complex coronary artery disease. SYNTAX makes interventionists
and surgeons come together, it may set the benchmark for MVD revascularization. PCI and CABG
should be considered complementary rather than competitive revascularization strategies. There is
no substitute for sound clinical judgment that takes into account the patient’s overall clinical pro-
ﬁle, functionality, co-morbidities, as well as the patient’s coronary anatomy. The SYNTAX Score
should be utilized to decide on treatment of patients with LM/MVD. Patients with low and inter-
mediate score can be treated with PCI or CABG with equal results. Those with high score do better
with CABG. SYNTAX trial showed that 66% of patients with 3VD or LMD are still best treatedsultant Cardiac Cardiologist,
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36 H.S. Alamri et al.with CABG. In the remaining 1/3 of patients with low syntax score, PCI may be considered as an
alternative to surgery. Finally, medical treatment should be optimized in patients going for CABG.
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Coronary Artery Bypass Grafting (CABG) was introduced in
1968 (Favaloro, 1968) and rapidly became the standard of care
for symptomatic patients with coronary artery disease (Faval-
oro, 1968; Buxton et al., 1998). Advances in coronary surgery
(e.g., off-pump CABG, smaller incisions, enhanced myocardial
preservation, use of arterial conduits, and improved postoper-
ative care) have reduced morbidity, mortality (Buxton et al.,
1998; Flynn et al., 2004; Janssen et al., 2004; Tavilla et al.,
2004; Barner, 2008). Percutaneous Coronary Intervention
(PCI) was introduced in 1977 (Gru¨ntzig, 1978). Experience with
this approach, coupled with improved technology, has made it
possible to adopt PCI as viable treatment option for patient
complex coronary disease who would have been referred for
CABG (Bittl, 1996; Serruys et al., 2006). Despite this advances,
the ideal revascularization treatment that is durable, less inva-
sive, carries insigniﬁcant morbidity and mortality is yet to be
determined. This has lead to the development of the so called
Appropriateness Criteria for Coronary Revascularization
(Patel et al., 2009a,b), in general, PCI was rated as appropriate
for acute myocardial injury and most scenarios where there was
signiﬁcant CAD associated with demonstrable ischemia and
symptoms despite adequate medical therapy. The degree of
appropriateness generally increased as the extent of myocar-
dium at risk increased until the 3-vessel disease threshold of
CAD extent was reached. For these patients, PCI was rated
as uncertain regardless of the presence of diabetes or left ven-
tricular dysfunction. PCI for left main CAD was scored as
inappropriate in all described settings. CABG was rated as
appropriate for 3-vessel and for left main CAD in all settings.
Although CABG remains the standard of care for patients
with >50% stenosis of the three coronary arteries and/or left
main stem stenosis (Hoffman et al., 2003; Serruys et al., 2005;
Editorial review, 2006; Taggart, 2009; Appropriateness of
myocardial revascularization, 2009), Percutaneous coronary
intervention (PCI) has progressed through simple balloon
angioplasty, to bare metal stents, and drug-eluting stents,
and has become a rival to CABG in patients with multivessel
coronary artery disease (CAD) or left main disease. However,
the need for repeat revascularization, in-stent stenosis, and
thrombosis remain the achilis heal of PCI.Various studies in recent years have compared CABG with
PCI including BMS & DES. The PCI without stents trials (e.g.
BARI, CAPRI, RITA, EAST, GABI, ERACI) (Bravata et al.,
2007) and with bare metal stent (BMS) (ARTS I, SOS, ERACI
II, MASS II, AWESOME) (Takagi et al., 2008). Data from the
majority of the randomized clinical trials showed that CABG
provides more effective angina relief and less need for repeat
revascularization, but offered no short term survival beneﬁt
over PCI, except in patients with diabetes. However, the rate
of strokes was signiﬁcantly increased in CABG patients (Brav-
ata et al., 2007; Takagi et al., 2008).
Interestingly, the recently published meta-analysis of the
BMS vs. CABG trials which was the ﬁrst to include long-term
follow-up data, did not show any signiﬁcant differences in the
rates of death, cardiovascular death, myocardial infarction,
cerebrovascular events and angina. Yet, again, higher rates
of target lesion revascularizations were observed in the PCI
group (Appropriateness of myocardial revascularization,
2009; Bravata et al., 2007). Two randomized studies (ARTS
II and ERACI III) determined the efﬁcacy of DES compared
to CABG in the setting of stable multivessel disease. Target
vessel revascularization was comparable to CABG in the
ARTS II (Serruys and Investigators, 2005) and ERACI III,
(Rodriguez Alfredo, 2006) studies. Recently published 3-year
data from the ERACI III, group reveals a major adverse car-
diac and cerebrovascular events (MACCE) rate of 22.7%,
equal to that of CABG (Rodriguez et al., 2007). Data showing
mortality beneﬁt for CABG in multivessel CAD compared to
PCI are mainly derived from registries, with the New York
registry data (Hannan and Wu, 2008) showing a mortality rate
reduction of at least 25% across all anatomic subgroups in
favor of CABG. The SOS (Coronary artery bypass surgery,
2002) was a randomized trial that also reported a mortality
beneﬁt for surgery over 1 year, but with an exceedingly low
death rate in the CABG arm (2% vs. 5%; P= 0.01). Meta-
analysis of 13 randomized clinical trials (Hoffman et al.,
2003) also demonstrated a 1.9% survival advantage for CABG
over PCI.
Randomized, controlled trials enrolled smaller numbers of
patients, and many of true trials were underpowered to detect
survival beneﬁt. Registries do have the advantage of analyzing
large number of real-life patients, but they provide observa-
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scale prospective randomized trials (such SYNTAX and
FREEDOM) comparing PCI to CABG in the today’s practice
are poised to improve our understanding of how to manage
CAD in the ERA of DES. In this manuscript we discuss the
SYNTAX trial in some details.Table 1 Outcomes at 2 years.
CABG
(n= 897) (%)
PCI
(n= 903) (%)
P Value
MACCE 16.3 23.4 <0.001
Death, stroke, Ml 9.6 10.8 0.44
All Cause Death 4.9 6.2 0.24
Stroke 2.8 1.4 0.03
Ml 3.3 5.9 0.01
Repeat revascularization 8.6 17.4 <0.0012. The SYNTAX trial
The SYNergy between percutaneous coronary interventionwith
TAXus and cardiac surgery (SYNTAX) compared PCI with
DES and CABG in patients with untreated 3VD and/or LMS
disease (Serruys et al., 2009b). SYNTAX is the ﬁrst randomized
prospective, multicenter, multinational, randomized, and con-
trolled all comers’ trial to compare PCI using drug-eluting stents
(DES) to CABG in patients with left main disease and three-
vessel disease. A total of 4337 patients with untreated 3VD or
LMDor both initially screened.About 3075 patients were found
eligible for the trial 1800 patients deemed suitable for the trial
were randomized at 85 sites and of the remaining 1077 patients,
198 patients were enrolled in the PCI registry and 1077 in the
CABG registry. Patients followed up at 30 days post procedure
and at 1, 6 12, 30 and 60 months. The primary end point of the
study: the compound clinical outcome constituted of death by
any cause, strokes, myocardial infarction, the necessity of re-
peated revascularization by PCI and/or CABG (deﬁned as
MACCE – Major Cardiovascular or Cerebrovascular Events)
at 12 months of follow-up I an attempt to assess the non-inferi-
ority of PCI compared to CABG.
After 1 year follow, the study failed to meet its primary end
point, with a relative hazard of 1.44 for excess MACE with
PCI. The primary endpoint of SYNTAX, 12-month binary
MACCE was signiﬁcantly higher in the PCI arm (12.4%
CABG vs. 17.8% P= 0.002) due, in large part, to increased
repeat revascularization (CABG 5.9% vs. PCI 13.5%). The
rate of repeat revascularization was signiﬁcantly higher among
patients in the PCI group than among those in the CABG
group (13.5% vs. 5.9%, P< 0.001). Most patients who under-
went repeat revascularization were treated with PCI rather
than CABG. The rate of stroke was signiﬁcantly higher with
CABG than with PCI at 12 months (see results at 2 years),
even though the two groups were well balanced with regard
to carotid artery disease and other risk factors for stroke
(2.2% vs. 0.6% P0.003).
The two groups had similar rates of death from any cause
or myocardial infarction and of the combined end point of
death from any cause, stroke, or myocardial infarction. About
3.5% in the CABG group versus 4.4% in the PCI group
(P= 0.37). The rate of death from cardiac causes was greater
with PCI than with CABG (3.7% vs. 2.1%, P= 0.05); the rate
of death from noncardiac causes, although not signiﬁcant, was
higher with CABG (1.4% vs. 0.7%, P= 0.13). Other data
showed that the rate of symptomatic graft occlusion was
3.4% in the CABG group, and the rate of stent thrombosis
in the PCI group 3.3% (P= 0.89). Analysis of secondary
end points showed that the two treatment groups had similar
rates of death from any cause, stroke, or myocardial infarction
(7.6% for PCI and 7.7% for CABG).
After 2 years follow-up; MACCE was signiﬁcantly in-
creased in PCI patients (CABG 16.3% vs. PCI 23.4%;
P= 0.0002); mainly attributable to an increased rate of repeatrevascularization in PCI-treated patients (CABG 8.6% vs. PCI
17.4%; P< 0.0001). The composite safety endpoint of death/
stroke/MI was comparable between the two groups (CABG
9.6% vs. PCI 10.8%; P= 0.44). The rate of MI was signiﬁ-
cantly increased in PCI patients (CABG 3.3% vs. PCI 5.9%;
P= 0.01), whereas stroke remained signiﬁcantly higher in
CABG patients (CABG 2.8% vs. PCI 1.4%; P= 0.03) after
2 years of follow-up, due to early increase in stoke rate.
Stroke rate over the second year was indistinguishable be-
tween the two arms (0.6% for CABG versus 0.7% for PCI;
P= 0.82). The ﬂattening of the difference in stroke was
replaced by an uptake in the MI rate during the same period.
Repeat revascularization rate, had narrowed to 3.7% for
CABG versus 5.6% for patients treated with stents after 1
year, and was no longer signiﬁcant (P= 0.06).
Serruys (ESC, 2009a) reported a statistically signiﬁcant de-
crease in the 2-year rate of major adverse cerebrovascular and
cardiac events (MACCE) in patients with a Syntax score = 33
who were treated with CABG vs. those treated with PCI using
a Taxus stent. For patients with a Syntax score <33, the 2-
year MACCE rate was similar between groups Tables 1–3
(Kim Dalton, 2009).
In the LM subgroup: at 2 years (Rodriguez et al., 2007)
MACCE rates were comparable between CABG and PCI-trea-
ted patients (CABG 19.3% vs. PCI 22.9%; P= 0.27). The im-
pact of lesion complexity on 2-year clinical outcomes was
estimated by examining patient outcomes relative to SYNTAX
Score tercile (Serruys et al., 2009b). Low SYNTAX Scores: the
rates of MACCE were not signiﬁcantly different between PCI
and CABG (CABG 17.4% vs. PCI 19.4%, P= 0.63). Interme-
diate SYNTAX Scores, there was a trend towards increased
MACCE with PCI (CABG 16.4% vs. PCI 22.8%, P= 0.06).
In the most complex patients (SYNTAX Scores P33), MAC-
CE was signiﬁcantly increased in patients treated with PCI
(CABG 15.4% vs. PCI 28.2%; P= 0.0001).
The CABG registry patients who are technically unsuitable
for PCI have the most complex lesion anatomy as expressed by
a higher SYNTAX score. In the CABG registry the 12 month
outcomes are: All Cause Death 2.5%, CVA 2.2%, MI 2.5%,
repeat revascularization 3.0%, and MACCE 8.8%.
Strengths of SYNTAX: (Serruys et al., 2009b) the study is a
prospective, multicenter trial in which a large number of pa-
tients were enrolled at 85 centres in Europe and the United
States. It attempted to include ‘‘all comers’’, with 71% of
screened patients enrolled in the randomized or registry co-
horts. While in previous less than 10% of screened patients
were included. The study used state-of-the-artCABG and
PCI (with arterial grafts and drug-eluting stents, respectively).
A ‘‘heartteam’’ consisting of an interventional cardiologist and
Table 2 First year vs. second year outcomes.
First year Second year
CABG (%) PCI (%) P Value CABG (%) PCI (%) P Value
Stroke 2.2 0.6 0.003 0.6 0.7 0.82
Ml 3.3 4.8 0.11 0.1 1.2 0.008
Repeat revascularization 5.9 13.5 <0.001 3.7 5.6 0.06
Table 3 MACCE by SYNTAX score: ﬁrst year vs. second year.
First year Second year
CABG (%) PCI (%) P Value CABG (%) PCI (%) P Value
Low (0–22} 14.7 13.6 0.71 17.4 19.4 0.63
Intermediate (23–32) 12.0 16.7 0.10 16.4 22.3 0.06
High (P33) 10.9 23.4 <0.001 15.4 28.2 <0.001
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appropriate treatment. A very useful part of the SYNTAX
trial was not only reinforcing a multi-disciplinary team ap-
proach but the introduction of the SYNTAX score.
Limitations of SYNTAX: (Serruys et al., 2009b; The Journal
of Thoracic and Cardiovascular Surgery, 2009) The follow-up
period was only 12–24 months; the outcomes of PCI andCABG
over a longer period of follow-up in patients with severe coro-
nary artery disease are unknown. Since most of the patients
(78%) were men, it is unknownwhether these ﬁndings are appli-
cable to women. The patients who underwent CABG were less
likely to receive optimal medical therapy (i.e., statins, aspirin
or other antiplatelet agents, and angiotensin-converting-enzyme
[ACE] inhibitors or angiotensin II-receptor antagonists), which
mayhave contributed to their increased risk of stroke. The inves-
tigators did not discuss whether the strokes were related to the
procedure or inﬂuenced by differences in the occurrence of atrial
ﬁbrillation, use of antiplatelet agents, or presence of risk factors
for atherosclerosis. The statistical power is reduced by short
duration and early reporting. The trial design, whichmay not re-
ﬂect real-world clinical treatment andmay not effectively isolate
the treatment effect to the primary outcome of the procedure
being studied. In SYNTAX, for example, a large difference in
secondary preventionmedical therapy resulted from the trial de-
sign. CABGpatients were signiﬁcantly under streated with aspi-
rin (84% vs. 91%), thienopyridine (15% vs. 71%), and statin
drugs (75%vs. 87%) comparedwith PCI patients. These factors
maybe relevant to the 50%ofCABGstrokes that occurredmore
than 30 days after operation.
Extensive post hoc subgroup analysis was undertaken to
establish a role for the SYNTAX score, which is a risk strati-
ﬁcation score based entirely on coronary anatomy and lesion
characteristics. This score is not yet externally validated or
published in detail, but it is known to contain risk adjustors
that are not signiﬁcant for CABG (in which coronary and le-
sion anatomy is largely irrelevant, as evidenced by registry re-
sults). The anatomic bias of the SYNTAX score may skew
decisions toward the use of PCI despite other patient risk fac-
tors that support an advantage for CABG.
Opinion regarding the meaning and potential effect of the
SYNTAX trial has been largely one-sided and aligned with
the paradigm that as long as PCI has no demonstrable mortal-
ity disadvantage, it remains the treatment of choice. As de-scribed, however, absolutely no justiﬁcation exists for even
implying that PCI is equivalent to CABG for safety outcomes
in this trial. In fact, the evidence supports the opposite conclu-
sion. The trial was underpowered to demonstrate safety other
than MACE (where CABG was shown to be signiﬁcantly supe-
rior), and the mortality trend favors CABG, with 26% excess
death at 1 year for PCI. Finally, the trial design actually
stacked the cards against PCI intervention by combining both
the hard end points of death, MI, and stroke, and the soft end
point, he need for revascularization, into a combined primary
end point. If the trial design had separated those end points,
the primary end point would have been equivalent.
2.1. Lessons learned
A multi-disciplinary team approach should be the standard of
care when recommending treatment in more complex coronary
artery disease. SYNTAX makes interventionists and surgeons
come together, it may set the benchmark for MVD revascular-
ization. PCI and CABG should be considered complementary
rather than competitive revascularization strategies. There is
no substitute for sound clinical judgment that takes into ac-
count the patient’s overall clinical proﬁle, functionality, co
morbidities, as well as the patient’s coronary anatomy.
The SYNTAX Score, which is now available free online,
should be utilized to decide on treatment of patients with
LM/MVD (Feldman, 2009). IT represents a great tool for a
better analysis of the angiogram, helps the interventional car-
diologist in decision-making and prognostication but also and
is predictive for postoperative outcome. The Score will be use-
ful indirectly to the heart surgeon when deciding for a surgical
option. Using the same score in order to keep track of indica-
tions with either PCI or CABG will be helpful during later fol-
low-up.
Patients with low and intermediate score can be treated with
PCIorCABGwith equal results. Thosewith high score dobetter
with CABG. Increasing SYNTAX Scores (and lesion complex-
ity) are related to increased adverse outcomes in PCI, whereas
outcomes of CABG are independent of SYNTAX Score.
Among patients in the PCI group with high SYNTAX scores
(=33), not only was the overall rate ofMACCE signiﬁcantly in-
creased, but also the rate of the composite components of death,
stroke, and MI (11.9% vs. 7.6%, respectively, in the PCI and
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approach should be avoided in patients with high SYNTAX
score. Therefore, patients with a high SYNTAX Score need an
‘‘individualized’’ approach, especially in the presence of diabetes
and/or with bifurcation lesions.
Based on a non-signiﬁcant difference in MACCE at 1 year,
the SYNTAX results suggest that 66% of all patients with
3VD or LM coronary artery disease are still best treated with
CABG. For the remaining 1/3 of such patients with a low
SYNTAX Score (0–22), PCI may be considered as an alterna-
tive to surgery (with the exception of insulin-dependent dia-
betic patients).
The mortality rate at 12 months was 4.3% in the PCI
Group and 3.5% in the Surgical Group. Even though the study
was not designed and did not have statistical power to analyze
differences in isolated outcomes, surgery showed a strong ten-
dency of improved survival over 1 year, with a 23% beneﬁt in
respect to death compared to PCI. Mortality is directly related
to syntax score. As with previous trials and registries, the
safety in terms of death, MI and stroke remained the same
for PCI and CABG in the SYNTAX trial. Furthermore, the
increase in repeat revascularization for PCI is much lower than
in any prior trials, despite a much more complex coronary
anatomy of patients studied.
The excess of early graft occlusion is offset by increase in
late stent thrombosis: the stent thrombosis risk should be con-
sidered when taking a decision. Stent thrombosis lead to AMI
in 100% of patients and death in 30% of them (Lancet, 2007;
NEJM, 2007). On the other hand, the occlusion rate of symp-
tomatic grafts was 3.4% over 12 months. This number is lower
than that classically reported of 10% of occlusion of venous
grafts over 1 year. Better surgical techniques allied to the inten-
sive use of statins and antiplatelet agents may be responsible
for the difference in these results. The prognosis of these com-
plications is also different. In drug-eluting stent thrombosis,
the mortality rate varies between 30% and 45% and the occur-
rence of myocardial infarction is greater than 80% of patients
affected (Iakovou et al., 2005; Wenaweser et al., 2008).
Stroke occurs mostly within the ﬁrst 30 post operative days
(Stettler, 2008; Bhatt et al., 2006; Goldstein, 2007; Rodrı´guez-
Ya´n˜ez et al., 2008; Steinhubl et al., 2002; Clopidogrel in Unsta-
ble Angina to Prevent Recurrent Events, 2001; TCT, 2009).
The incidence of strokes after CABG is mainly related to the
age of the patient and the presence of atherosclerotic plaque
in the ascending and transverse aorta. Peri-operative athero-
embolism from the aorta is responsible for at least one-third
of the cases of strokes after CABG due to the handling of
the ascending aorta or aortic arch during cannulation, aortic
clamping, and preparation of proximal anastomoses or of
the arterial cannula ﬂow. Recent more rigorous methods to de-
tect advanced atherosclerosis of the ascending aorta, as well as
surgical strategies, such as routine ultrasound assessment of
carotid arteries in patients above the 65 years, the use of no-
touch technique of off-pump surgery, may reduce the mobili-
zation of aortic atheroma and prevent the occurrence of this
event (Vallely et al., 2008; Calaﬁore et al., 2002; Prapas
et al., 2007). Stroke can be prevented and/or minimized by
better management of the antiplatelet therapy. The patients
who underwent CABG were less likely to receive optimal med-
ical therapy (i.e., statins, aspirin or other antiplatelet agents,
Angiotensin-converting enzyme (ACE) inhibitors or angioten-
sin II-receptor antagonists).Angina and Quality of life: While CABG is effective in
reducing angina. Among patients undergoing revasculariza-
tion for left main or 3-vessel CAD, angina relief was better
with CABG than DES at 6 and 12 months. The magnitude
of beneﬁt was smaller than in previous CABG vs. PCI compar-
isons, however, and below the threshold that most patients
would ﬁnd clinically meaningful. All other QOL endpoints
favored PCI at 1 month, although these differences were tran-
sient and largely resolved by 6 months.
Complete revascularization was performed in only 63% of
the patients submitted to CABG against 57% in PCI; the goal
should be complete revascularization. Arterial graft: More use
of arterial graft should be encouraged; LIMA was used in 97%
but BIMA artery in 27% and all arterial grafts in only 19%.
While the saphenous vein has been considered as the predom-
inant graft, venous graft atherosclerosis continues to be the
major cause of late failure of CABG.
Diabetics with CAD had worse prognosis than non-diabet-
ics regardless of treatment option (Mathew et al., 2004; Ser-
ruys, 2006; Kapur et al., 2009; Lange and Hillis, 2009).
Compared with non-diabetic patients, those with diabetes
had more complex lesions and a higher incidence of co morbid-
ities. The 1-year MACCE rate was signiﬁcantly higher with
PES due to an increase in repeat revascularizations. Other end-
points were similar between the DES and CABG groups,
although there were trends toward higher cardiac death rates
with DES and more strokes with CABG. Looking only at pa-
tients with the greatest anatomical complexity (Syntax
scores = 33), the mortality advantage with CABG compared
with PES was statistically signiﬁcant for both diabetics
(4.1% vs. 13.5%; P= 0.04) and non-diabetics (2.2% vs.
6.1%; P= 0.04). Insulin-treated diabetes who received DES
showed a trend toward higher mortality (12.5%) than similar
patients who underwent CABG (5.7%; P= 0.12).Also had
higher mortality than patients with non-insulin-dependent dia-
betes who received PES (5.8%; P= 0.07).Patient with DM
(especially IDDM), with intermediate or high syntax score bet-
ter treated with CABG. CARDIA trial, in pre-speciﬁed sub-
group analyses, including DES vs. BMS, 2-vessel vs. 3-vessel
disease, insulin-treated vs. not insulin-treated, female vs. male,
and age <65 years vs.P65 years, outcomes showed no signif-
icant differences. Only DES and 2-vessel disease appeared to
favor PCI over CABG for the primary endpoint (11.6% vs.
12.4% for BMS and 8.9% vs. 9.8% for 3-vessel disease, respec-
tively). However, all subgroup analyses were underpowered,
according to the authors (Kapur et al., 2009).
Medical treatment: should be optimized in all patients, it is
surprising to see that in the SYNTAX trial, only 74.5% of pa-
tients in the CABG group received statin therapy, whereas in
the PCI group, 86.7% of patients received statin therapy
(P< 0.001).
How patient should be treated according to SYNTAX? If
safe and complete revascularization is feasible with either
PCI or CABG – as was true in roughly 60% of the patients
in the SYNTAX study – an assessment of coronary anatomical
characteristics should be performed, and a SYNTAX score as-
signed. The presence of complex coronary anatomical features
(assigned a high SYNTAX score) identiﬁes patients with an in-
creased risk of a suboptimal outcome with PCI; they should be
encouraged to undergo CABG. Conversely, patients with less
complex coronary anatomical features (i.e., a low SYNTAX
score) should be presented with the advantages and disadvan-
40 H.S. Alamri et al.tages of each procedure and allowed to choose between them.
Irrespective of which procedure is performed, the patient
should receive optimal medical therapy involving an antiplate-
let agent (or agents), a statin, and an ACE inhibitor, if
appropriate.
The patient has the right to know: that PCI treats the cul-
prit lesion whereas CABG bypasses the lesion therefore treat-
ing not only the culprit but also future lesions (Eagle et al.,
2004). PCI associated with higher need of repeat revasculariza-
tion, a trend toward higher likelihood of cardiac death (PCI
3.7% vs. CABG 2.1%, P= 0.05); and (MI (CABG 3.3% vs.
PCI 5.9%; P= 0.01). CABG associated with higher rate of
CVA (CABG 2.8% vs. PCI 1.4%; P= 0.03).
The results of SYNTAX study have a number of implica-
tions to medical management of CAD; (Serruys et al., 2009a;
ESC, 2009b) when designing the study, interventional cardiol-
ogists had proposed using intensive post-procedural medica-
tions such as antiplatelets, angiotensin-converting (ACE)
inhibitors, statins and beta-blocker. These are frequently
administered following PCI, with well established beneﬁts
(Serruys et al., 2005). While this practice was upheld in the
SYNTAX study, the same degree of intensive therapy was
not practiced in the CABG arm of the study. This minor var-
iation in the standard of care between the two groups is not a
new occurrence; in practice, this presents only a small differ-
ence as patients soon return to the care of a cardiologist after
surgical intervention.
The lower rate of stroke observed among the PCI group is
attributed to the higher use of antiplatelet therapy in this co-
hort of patients following the medical procedure and its pro-
tective effects against thromboembolic events (Goldstein,
2007). It is therefore possible that this beneﬁt could be ex-
tended to patients undergoing CABG if the use of additional
antiplatelet drugs were adopted as the norm in practice (Eagle
et al., 2004).3. Conclusion
As the author’s conclude CABG remains the standard of care
for these complex patients; however, an assessment of world-
wide clinical practice in 2004 indicated that 29% of patients
with complex disease were already having PCI, despite the
absence of any supportive evidence and against all guidelines.
The SYNTAX study, which was speciﬁcally designed to reﬂect
real-world practice, has indicated that in 2009, for two-thirds
of patients with complex coronary disease, cardiac surgery is
still the optimal method of revascularization. In the remaining
one-third, PCI offers a suitable alternative. However, a full
and frank discussion between doctor and patient is required
to ensure that a completely informed decision is made.
Historically, these patients were already being selected by
intervention lists for PCI; these decisions are now justiﬁed by
clinical evidence, and, by utilizing the SYNTAX score, these
patients can be identiﬁed more systematically. One important
take-home message from the study is that the method of revas-
cularization must be individualized taking into account not
only coronary anatomy but also the patient’s co morbidities
and personal preference.
The editorial associated with the SYNTAX trial publica-
tion (Lange and Hillis, 2009) was generally balanced and calls
for separating CAD diagnosis and treatment to allow formulti-disciplinary decision-making regarding treatment selec-
tion. Recommendations must be guided by a patient-centric
process that results in reasoned agreement between colleagues
rather than procedural advocacy. It is incumbent upon car-
diac surgeons to own this disease through knowledge and
experience and not own the patient or the procedure. This
paradigm includes a responsibility to ensure that CABG
patients receive optimal medical management for the rest of
their lives.
Although the evidence supports the appropriateness of
CABG for virtually all scenarios of signiﬁcant CAD, it is no
more the treatment of choice for all patients than is PCI.
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